Early Look: Nutriband Inc. (NASDAQ: NTRB) Tops Our Pre-Market Watchlist This Morning

*Sponsored by Nutriband Inc. Just Announced! Nutriband Inc. (NASDAQ: NTRB) is Our Next Potential Breakout  Idea For Friday Morning! And Here’s Why… Analyst Coverage: Noble Capital’s Robert LeBoyer Set A $13 Target, Suggesting Over 103% Upside Potential. Insider Confidence: Over 54% Insider Ownership As Of 2/6/2025. Low Float & Market Recognition : Under 5.1M Shares In The Float, With An Approx. 202% Move In One Week This January. Technical Strength: Trending Above Key Moving Averages, Signaling Momentum Potential. Take a Look at Nutriband Inc. (NASDAQ: NTRB) Before  The Bell Rings… February 7, 2025 Dear Reader, An under the radar company with a recent history of making significant swings is showing strength again, and it has our full attention. With a low float, strong insider backing, and an innovative approach to dr-ug delivery—this one stands out.  When momentum picks up in a setup like this, it’s worth paying attention. Let’s not waste time. Nutriband Inc. (NASDAQ: NTRB) is leading our pre-market watchlist this morning. Keep reading to see why… Let’s call it like it is—few biotech companies are pushing boundaries quite like Nutriband Inc. (NASDAQ: NTRB). While others stick to tired formulas and incremental changes, Nutriband Inc. (NASDAQ: NTRB) is establishing itself as a leader in the development of advanced transdermal technologies, addressing some of the most critical challenges in healthcare today. With a low float, of less than 5.1M shares listed, we’re keeping a close eye on Nutriband Inc. (NASDAQ: NTRB) because this scarcity could lead to the potential for significant swings if demand begins to change. In fact, Nutriband Inc. (NASDAQ: NTRB) recently moved approximately 202% in one week, from $3.90 on January 16th to $11.78 on January 23, 2025. Currently trending above several key moving averages, Nutriband Inc. (NASDAQ: NTRB) is showing strong technical momentum.  With its 20-day moving average at $6.44, 50-day at $5.21, 100-day at $5.57, and 200-day at $5.42, (NTRB) is currently trending above all long-term indicators tracked by Barchart—a bullish signal that could suggest further upside potential.  Additionally, its year-to-date moving average of $6.15 reinforces the notion that (NTRB) has been maintaining strength despite broader market fluctuations. Backing this momentum, insider ownership stands at over 54% as of (yesterday)—an exceptionally strong vote of confidence from those who know the company best. With more than half of all shares held by insiders, leadership is signaling long-term commitment and belief in future growth. This combination of technical strength and a market cap under $75M, could position (NTRB) as a high-growth candidate compared to larger players in the same space. Just over two weeks ago, Noble Capital’s Robert LeBoyer initiated coverage on (NTRB) with a Bullish Rating and a $13 target, which suggests over 103% upside potential from today’s $6.39 level. At the heart of this optimism is Nutriband Inc. (NASDAQ: NTRB)’s Phase 1 clinical trial, which is expected to showcase the effectiveness of its abuse-deterrent technology, setting up for an NDA filing by late 2025 and potential FDA approval in 2026. With a clear roadmap ahead and momentum at its back, Nutriband Inc. (NASDAQ: NTRB) is earning attention for all the right reasons. In a year where many companies struggled to stay relevant, (NTRB) refused to slow down—doubling down on its strategy, solidifying its position, and delivering results that speak for themselves. Trailblazing with AVERSA™ Fent-a-nyl Nutriband Inc. (NASDAQ: NTRB)’s crown jewel, AVERSA™ Fent-a-nyl, has redefined what’s possible in abuse-deterrent therapeutics.  This groundbreaking transdermal patch is designed not just to combat misuse but to revolutionize patient safety across the board.  With support from Kindeva Dr-ug Delivery, Nutriband Inc. (NASDAQ: NTRB) made significant headway in 2024: Completed pivotal validation studies, advancing the product closer to market readiness. Established a clear regulatory path for its New Application (NDA) submission in 2025, relying on a streamlined single Phase 1 Human Abuse Potential study. This isn’t just a pipe dream, either. If approved, AVERSA™ Fent-a-nyl is projected to rake in U.S. sales of $80M to $200M annually—a staggering testament to its market potential. Global Footprint Grows: Nutriband (NTRB) Now Holds  IP Protection in 46 Countries Nutriband Inc. (NASDAQ: NTRB) isn’t just thinking local; they’re playing on a global stage. With patent approvals in China and Hong Kong, the company now boasts intellectual property coverage in 46 countries.  A U.S. Notice of Allowance for the AVERSA™ trademark further solidified their footing, giving competitors a clear signal: Nutriband Inc. (NASDAQ: NTRB) is here to lead. Strategic Fiscal Growth Numbers don’t lie.  Nutriband Inc. (NASDAQ: NTRB) reported record-breaking revenues in 2024, with their contract manufacturing arm, Pocono Pharma, leading the charge: A Q3 revenue of over $645k, representing a 51% year-over-year increase. Strengthened financial reserves, courtesy of $8.4M in fresh capital from a private placement. This fiscal foundation gives Nutriband Inc. (NASDAQ: NTRB) the firepower it needs to push AVERSA™ Fent-a-nyl over the finish line while continuing to innovate. Nutriband Inc. (NTRB) Gears Up for FDA Submission—Could AVERSA™ Fent-a-nyl Hit the Market in 2025? Regulatory Milestones Await: The centerpiece of Nutriband Inc. (NASDAQ: NTRB)’s 2025 ambitions is the NDA submission for AVERSA™ Fent-a-nyl. With pivotal data in hand and no need for extended Phase 2 or Phase 3 trials, the company anticipates an expedited review process.  Translation? AVERSA™ Fent-a-nyl could be on the market before the year is out. Scaling for Success: Preparation for commercialization is already underway. Nutriband Inc. (NASDAQ: NTRB) is scaling its partnership with Kindeva Dr-ug Delivery to ensure manufacturing excellence.  Simultaneously, the company is laying the groundwork for international licensing and distribution agreements, proving that they aren’t content with U.S. dominance—they’re going global. A Pipeline with Potential: AVERSA™ Fent-a-nyl is just the beginning. Nutriband Inc. (NASDAQ: NTRB) is also advancing AVERSA™ Buprenorphine and exploring additional transdermal applications.  If these developments live up to their promise, Nutriband Inc. (NASDAQ: NTRB) could unlock an entirely new revenue stream, with AVERSA™ Buprenorphine alone estimated to generate $130M annually. Nutriband Inc. (NASDAQ: NTRB) Secures Key Retail Partnerships With Target, Walmart, Walgreens & CVS Nutriband Inc. (NASDAQ: NTRB) isn’t relying on just one path to success. The company’s manufacturing divisions—Pocono Pharma and Active Intelligence—are building momentum on multiple fronts. Expanded partnerships with retail giants like Target, Walmart, Walgreens, and CVS. Delivered innovative kinesiology and consumer health products, including an exclusive supplier agreement with Fit For Life Group, which represents Adidas, Reebok, and New Balance. Launched a Mosquito Repellent Patch in Costa Rica, marking their entry into the lucrative Central and South American markets. Nutriband Inc. (NASDAQ: NTRB) Takes On the Opi-oid Crisis With Game-Changing Innovation Let’s be clear—the opi-oid crisis remains one of the most urgent public health challenges of our time. Nutriband Inc. (NASDAQ: NTRB) isn’t just talking about solutions; they’re delivering them.  The AVERSA™ technology represents a paradigm shift in patient safety, offering a tangible way to reduce misuse, accidental exposure, and diversion of high-risk therapeutics. As CEO Gareth Sheridan aptly put it, Nutriband Inc. (NASDAQ: NTRB) is “on the brink of a transformative period in its history.”  And he’s not wrong.  The company has not only set the stage for regulatory and commercial success but also laid a solid foundation for long-term growth. Innovation Meets Impact: Nutriband (NTRB) Is Reshaping Healthcare Nutriband Inc. (NASDAQ: NTRB) isn’t just playing in the big leagues—it’s rewriting the rulebook. With AVERSA™ Fent-a-nyl on the cusp of commercialization, an ever-expanding pipeline, and strong fiscal performance, the company is positioning itself to drive innovation and make a real-world impact in healthcare. For those watching from the sidelines, here’s your wake-up call.  Nutriband Inc. (NASDAQ: NTRB) is not just about innovation; it’s about making a meaningful impact. See Nutriband Inc. (NASDAQ: NTRB)’s corporate presentation here. 7 Reasons Why Nutriband Inc. (NASDAQ: NTRB) is Topping Our Pre-Market Watchlist This Morning… 1. Recent Analyst Coverage: Noble Capital’s Robert LeBoyer initiated coverage with a $13 target, suggesting over 103% upside potential from current levels. 2. Low Float & Market Recognition: With under 5.1M shares in the float, Nutriband Inc. (NASDAQ: NTRB) has shown its potential for significant swings, including an approx. 202% move in a single week this January. 3. Technical Strength: Currently trending above multiple key moving averages, signaling potential for continued momentum. 4. Strong Insider Commitment: As of 2/6/2025, over 54% of shares are held by insiders, reflecting long-term confidence from those closest to the company. 5. Breakthrough Innovation: With AVERSA™ – Nutriband Inc. (NASDAQ: NTRB) is advancing abuse-deterrent technology with regulatory milestones on the horizon. 6. Expanding Global Presence: With patents in 46 countries and recent U.S. trademark approvals, Nutriband Inc. (NASDAQ: NTRB) is building a worldwide footprint. 7. Strategic Industry Partnerships: Collaborations with Kindeva Dr-ug Delivery, a former 3M division, to accelerate AVERSA™ technology commercialization. Consider Adding Nutriband Inc. (NASDAQ: NTRB) to  Your Radar This Morning… Nutriband Inc. (NASDAQ: NTRB) is aiming to build momentum with its AVERSA™ abuse-deterrent technology, a growing product pipeline, and patent protection in 46 countries. With a low float under 5.1M shares, over 54% insider ownership, and technical indicators lining up, the company remains one to watch. And just last month, (NTRB) moved approx. 202% in one week, showing how quickly things can change when interest picks up. With upcoming regulatory milestones and a bullish outlook from analysts, we’ll be keeping a close eye on what happens next. We have all eyes on (NTRB) right now. Take a look before the bell rings.  I’ll follow up with you shortly—keep a lookout for my next update. Sincerely, Jeff Ackerman Managing Editor Stock News Trends StockNewsTrends.com (“StockNewsTrends” or “SNT” ) is owned by TD Media LLC, a single member limited liability company. Data is provided from third-party sources and StockNewsTrends is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SNT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owner of TD Media LLC owns and operates stocknewstrends . com (“SNT”). From time to time, SNT will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: stocknewstrends.com/disclosure/  *Pursuant to an agreement between TD Media LLC and Nutriband Inc., TD Media LLC has been hired for a period beginning on 02/06/2025 and ending on 02/07/2025 to publicly disseminate information about (NTRB:US) via digital communications. Under this agreement, TD Media LLC has been paid one hundred thousand USD (“Funds”). To date, including under the previously described agreement, TD Media LLC has been paid three hundred twenty-five thousand USD (“Funds”). These Funds were part of the funds that TD Media LLC received from Nutriband Inc., the issuer of (NTRB:US). Neither TD Media LLC or its member owns shares of (NTRB:US). Please see important disclosure information here: https://lifewatermedia.com/disclosure/ntrb/#details

TD Media LLC | 5826 New Territory Blvd. Unit #2144 | Sugar Land, TX 77479 US Unsubscribe | Update Profile | Constant Contact Data Notice